知镜 Cognispect · 医学文献与研究工作台

Duration of antibiotic therapy for bacteraemia in immune compromised hosts-a post-hoc subgroup analysis of the Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) randomized clinical trial.

Hamani M, Pinto R, Lee TC, MacFadden D, McDonald EG, Sligl W, Fowler RA, Daneman N, BALANCE consortium.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2026-06-09 · PMID 42264033

文献摘要

Objectives The Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) randomized clinical trial demonstrated 7 days to be noninferior to 14 days of antibiotics for bacteraemia. Uncertainty remains as to whether shortened treatment durations are sufficient for immune compromised patients. Methods BALANCE excluded patients with neutropenia ( 9 /L) and transplantation but allowed enrolment of other forms of immune compromise; this post-hoc subgroup analysis focused on these immune compromised patients. The primary outcome was 90-day mortality. The primary analysis was in the intention-to-treat population with sensitivity analyses among the modified intention-to-treat population limited to those who survived ≥7 days. Results Among BALANCE patients, 1037 (28.7%) were considered immune compromised; 530 were randomized to receive 7 days of antibiotics and 507 to receive 14 days. The most common types of immune compromise included solid malignancies (75.4%), leukaemia/lymphoma (9.7%), chemotherapy (15.4%), corticosteroid use (4.7%), and HIV/AIDS (2.3%). Despite being formally excluded, a small number of neutropenic patients were enrolled (2.5%). Patients received a median (interquartile range) of 8 (7-11 days) versus 14 (14-15 days) days of antibiotics in the two arms. All-cause 90-day mortality in the intention-to-treat population was 106/528 (20.1%) in the 7 days arm and 120/507 (23.7%) in the 14 days arm (risk difference, -3.6%; 95% CI, -8.6-1.4; p = 0.16). In the modified intention-to-treat analysis, 90-day mortality was 104/526 (19.8%) in the 7 days arm and 117/504 (23.2%) in the 14 days arm (risk difference, -3.4%; 95% CI -8.5-1.6, p = 0.18). Conclusions This post-hoc analysis of the immune compromised subgroup of the BALANCE randomized controlled trial suggests that the shorter treatment duration was sufficient for bacteraemia in these patients.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。